FDA
-
-
-
-
-
-
-
Biotech Bulls Stampede as Clinical Wins and Milestones Fuel Momentum
-
-
-
-
-
-
-
Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up
-
-
-
-
-
-
-
Edgewise Therapeutics adds Christopher Martin to board of directors
-
-
-
-
-
-
-
Edgewise Therapeutics (EWTX) PT Raised to $49 at RBC Capital
-
-
-
-
-
-
-
Edgewise Therapeutics Inc. (EWTX) Reports Positive Results on Sevasemten Program
-
-
-
-
-
-
-
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
-
-
-
-
-
-
-
Edgewise Provides Statement Regarding Company’s Relationship with Dr. Han Phan at Rare Disease Research
-
331,653 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

